Hoth Therapeutics announces collaboration for CLEER-001 Phase 2a clinical trial

Hoth Therapeutics announced the activation of Washington University School of Medicine in St. Louis as the first clinical site in the CLEER-001 Phase 2a clinical trial of HT-001 for the treatment for rash and skin disorders associated with epidermal growth factor receptor, or EGFR, inhibitor therapy. EGFR inhibitors are critical therapeutic agents for the treatment of non-small cell lung cancer, or NSCLC, pancreatic cancer, colorectal cancer, squamous-cell carcinoma of the head and neck, and breast cancer. Hoth is conducting the CLEER-001 clinical trial in the United States.